IBRANCE (Palbociclib) 75 mg & 125 mg Capsules – Breast Cancer Treatment HR+/HER2
EGP40000
IBRANCE (Palbociclib) 75 mg & 125 mg Capsules – Breast Cancer Treatment HR+/HER2-
Uses and Benefits
IBRANCE (Palbociclib) is indicated for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer in combination with endocrine therapy. As a selective CDK4/6 inhibitor, it blocks proteins that drive cell cycle progression, thereby slowing tumor growth and delaying disease progression.
- Targeted Mechanism: Inhibits CDK4/6 to control proliferation in HR+ breast cancer cells.
- Improved Outcomes: When combined with Letrozole or Fulvestrant, it can significantly extend progression-free survival.
- Quality of Life: Delays the need for chemotherapy for many patients, with manageable side effects for most.
Dosage and Administration
The usual starting dose of IBRANCE is 125 mg once daily for 21 consecutive days, followed by 7 days off treatment, forming a 28-day cycle. Dose reductions to 100 mg or 75 mg may be required depending on tolerance and side effects.
- With Food: Take at the same time each day with food. Swallow capsules whole—do not chew, crush, or open.
- Missed Dose: Skip the missed dose and take the next one as scheduled. Do not double up.
- Monitoring: Regular blood tests are required to monitor neutrophil counts and organ function.
Possible Side Effects
Not everyone will experience side effects, but common reactions include:
- Neutropenia (low white blood cell count), increased infection risk
- Fatigue and weakness
- Nausea, vomiting, or diarrhea
- Hair thinning (usually mild)
- Decreased appetite
- Mouth sores
Warnings and Precautions
- Pregnancy & Breastfeeding: Not recommended; discuss effective contraception.
- Infection Risk: Practice good hygiene and avoid close contact with sick individuals.
- Pre-existing Conditions: Discuss liver or kidney issues with your physician.
- Lab Monitoring: CBC and liver function tests should be performed regularly.
Drug Interactions
IBRANCE is metabolized by CYP3A enzymes. Concomitant use with strong CYP3A modulators can alter drug exposure.
- Avoid strong CYP3A inhibitors: e.g., Ketoconazole, Clarithromycin, Itraconazole.
- Avoid strong CYP3A inducers: e.g., Rifampin, Carbamazepine, Phenytoin, St. John’s Wort.
- Disclose all products: Tell your doctor about all medicines, vitamins, and herbal supplements.
Customer Reviews
“IBRANCE with Letrozole stabilized my disease. Side effects were manageable compared to chemo.”– Sarah M.
“Genuine Pfizer product and quick delivery. Great support team.”– David R.
“Dose reduction to 100 mg helped with early nausea and fatigue.”– Lina K.
Related Products
- Nexavar 200 mg Tablets – Targeted Cancer Therapy
- Stivarga 40 mg – Advanced Cancer Treatment
- Opdivo – Immunotherapy for Cancer
Frequently Asked Questions (FAQs)
1. What is IBRANCE used for?
It is used with endocrine therapy for HR-positive, HER2-negative advanced or metastatic breast cancer.
2. How does IBRANCE work?
As a CDK4/6 inhibitor, it slows cancer cell division by blocking proteins that drive the cell cycle.
3. What is the usual dosage?
125 mg once daily for 21 days, followed by 7 days off (28-day cycles). Doctors may adjust to 100 mg or 75 mg.
4. Can I use IBRANCE during pregnancy?
No, it is not recommended during pregnancy or breastfeeding.
5. What are common side effects?
Neutropenia, fatigue, nausea, diarrhea, hair thinning, and mouth sores.
6. Do I need lab monitoring?
Yes. Regular CBC and liver function tests are typically required.
7. Can men take IBRANCE?
Yes, men with HR+/HER2- metastatic breast cancer may also be treated with IBRANCE plus endocrine therapy.
8. What should I do if I miss a dose?
Skip the missed dose and take the next one as scheduled. Do not take two doses at once.
9. Does food matter?
Yes, take the capsule with food at the same time each day.
10. How long will I need treatment?
Duration depends on response and tolerability—your oncologist will determine ongoing therapy.
Conclusion
IBRANCE (Palbociclib) 75 mg & 125 mg offers targeted control of HR+/HER2- advanced breast cancer, delaying progression and extending the effectiveness of endocrine therapy with a manageable safety profile for many patients.
For authentic Pfizer IBRANCE and fast shipping, order now from No Style Like and get expert guidance with every purchase.
| التركيز |
|---|
